Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18640394 | 0.85 | USP2 (0.60) | USP2MAPTKMT2AL3MBTL1HTT | |
| SCHEMBL6647891 | 0.85 | USP2 (0.83) | USP2MAPTKMT2APOLBALKBH5 | |
| SCHEMBL23456094 | 0.82 | USP2 (0.96) | USP2MAPTKMT2APOLBALKBH5 | |
| SCHEMBL13990231 | 0.80 | USP2 (1.00) | USP2MAPTKMT2APOLBALKBH5 | |
| SCHEMBL29803137 | 0.80 | USP2 (0.73) | USP2MAPTKMT2AALDH1A1ALOX15 | |
| SCHEMBL4983013 | 0.79 | KDM5B (0.54) | POLBTDP1L3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL29802844 | 0.79 | ACHE (0.69) | USP2KMT2APOLBMAPK1 | |
| SCHEMBL29802720 | 0.79 | USP2 (0.58) | USP2MAPTKMT2APOLBTDP1 | |
| SCHEMBL15456392 | 0.76 | USP2 (0.78) | USP2MAPTKMT2APOLBALKBH5 | |
| SCHEMBL2794020 | 0.76 | MAPT (0.53) | USP2MAPTL3MBTL1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765053-B2 | Methods of treatment using selective 5-HT2A inverse agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2017-06-15 | — | — | US | disclosed |
| EP-1787984-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARM INC (US) | 2016-08-18 | — | — | US | disclosed |
| US-9296694-B2 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150259291-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARMACEUTICALS INC. | 2015-09-17 | — | — | US | disclosed |
| US-20110301191-A1 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2011-12-08 | — | — | US | disclosed |
| US-20090186921-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2007124136-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060194834-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | disclosed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | disclosed |
| US-6756393-B2 | AMIDES AND UREAS N-SUBSTITUTED WITH PIPERIDINE OR NORTROPANE; SEROTONIN INVERSE AGONISTS OR ANTAGONISTS; ANTIPSYCHOTIC | ACADIA PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | disclosed |
| CN-1443167-A | Azacyclo compounds for the treatment of 5-hydroxytryptamine related disorders | ACADIA PHARM INC (US) | 2003-09-17 | — | — | CN | disclosed |
| EP-1263729-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Acadia Pharmaceuticals Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | disclosed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259291-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | USP2 3176/4885MAPT 2692/4885KMT2A 958/4885 |
| US-20110301191-A1 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | USP2 2884/4885MAPT 3060/4885KMT2A 1969/4885 |
| US-20060194834-A1 | Azacyclic compounds | HTR6, HTR5A, HNMT | USP2 3949/4885MAPT 3047/4885KMT2A 1270/4885 |
| US-20090186921-A1 | AZACYCLIC COMPOUNDS | HTR6, HTR5A, HNMT | USP2 3949/4885MAPT 3047/4885KMT2A 1270/4885 |
| US-20030220316-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | USP2 3176/4885MAPT 2692/4885KMT2A 958/4885 |
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | USP2 3176/4885MAPT 2692/4885KMT2A 958/4885 |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | HTR4, HTR3B, HTR2A | USP2 3678/4885MAPT 3583/4885KMT2A 710/4885 |
| US-20050014757-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | USP2 3176/4885MAPT 2692/4885KMT2A 958/4885 |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | USP2 2884/4885MAPT 3060/4885KMT2A 1969/4885 |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | USP2 3176/4885MAPT 2692/4885KMT2A 958/4885 |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | HTR2A, HTR1A, HTR1B | USP2 3794/4885MAPT 2162/4885KMT2A 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.